The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Revenues | 216,105 |
| Cost of goods sold excluding amortization | 13,044 |
| Research and development | 109,271 |
| Selling, general and administrative | 237,951 |
| Intangible asset amortization | 7,007 |
| Other income | 12,521 |
| Provision (benefit) for income taxes | 81,827 |
| Net income (loss) | -220,474 |
| Depreciation of property and equipment | 1,103 |
| Stock-based compensation | 9,474 |
| Amortization of premiums and accretion of discounts on marketable securities | 2,053 |
| Loss on sales of marketable securities | 0 |
| Intangible asset amortization | 7,007 |
| Right-of-use asset amortization | 3,807 |
| Deferred income taxes | 81,443 |
| Other non-cash adjustments, net | -1,943 |
| Accounts receivable | 7,463 |
| Prepaid expenses and other assets | 12,067 |
| Inventory | 3,466 |
| Accounts payable and other liabilities | 15,820 |
| Product revenue allowances | 15,484 |
| Net cash provided by (used in) operating activities | -109,442 |
| Asset acquisition | 0 |
| Purchases of property and equipment | 998 |
| Purchases of marketable securities | 112,379 |
| Sales and maturities of marketable securities | 208,237 |
| Net cash provided by (used in) investing activities | 94,860 |
| Principal payments on finance leases | 1,991 |
| Tax obligations paid in connection with settlement of restricted stock units | 915 |
| Net cash provided by (used in) financing activities | -2,906 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 23 |
| Net change in cash, cash equivalents and restricted cash | -17,465 |
| Cash and cash equivalents at beginning of period | 102,785 |
| Cash and cash equivalents at end of period | 85,320 |
Vanda Pharmaceuticals Inc. (VNDA)
Vanda Pharmaceuticals Inc. (VNDA)